- Home
- MNPR vs ALMS Comparison
MNPR vs ALMS Comparison
Compare MNPR & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- ALMS
- Stock Information
- Founded
- MNPR 2014
- ALMS 2021
- Country
- MNPR United States
- ALMS United States
- Employees
- MNPR N/A
- ALMS N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- MNPR Health Care
- ALMS
- Exchange
- MNPR Nasdaq
- ALMS NYSE
- Market Cap
- MNPR 244.1M
- ALMS 260.6M
- IPO Year
- MNPR 2019
- ALMS 2024
- Fundamental
- Price
- MNPR $40.33
- ALMS $5.64
- Analyst Decision
- MNPR Strong Buy
- ALMS Strong Buy
- Analyst Count
- MNPR 5
- ALMS 7
- Target Price
- MNPR $49.60
- ALMS $28.17
- AVG Volume (30 Days)
- MNPR 30.6K
- ALMS 1.2M
- Earning Date
- MNPR 05-08-2025
- ALMS 05-15-2025
- Dividend Yield
- MNPR N/A
- ALMS N/A
- EPS Growth
- MNPR N/A
- ALMS N/A
- EPS
- MNPR N/A
- ALMS N/A
- Revenue
- MNPR N/A
- ALMS N/A
- Revenue This Year
- MNPR $34.06
- ALMS N/A
- Revenue Next Year
- MNPR N/A
- ALMS N/A
- P/E Ratio
- MNPR N/A
- ALMS N/A
- Revenue Growth
- MNPR N/A
- ALMS N/A
- 52 Week Low
- MNPR $1.72
- ALMS $3.18
- 52 Week High
- MNPR $54.30
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- MNPR 56.65
- ALMS N/A
- Support Level
- MNPR $36.80
- ALMS N/A
- Resistance Level
- MNPR $43.00
- ALMS N/A
- Average True Range (ATR)
- MNPR 5.32
- ALMS 0.00
- MACD
- MNPR 0.94
- ALMS 0.00
- Stochastic Oscillator
- MNPR 63.41
- ALMS 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.